menu
    • menu
    [{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Sectoral Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Sectoral Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Sectoral Asset Management"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Series C Financing","leadProduct":"Eneboparatide","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Sofinnova Partners","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Sofinnova Partners"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"AZP-40XX","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Amolyt Pharma \/ Amolyt Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Amolyt Pharma \/ Amolyt Pharma"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Eneboparatide","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"PeptiDream","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"AZP-3813","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amolyt Pharma \/ PeptiDream","highestDevelopmentStatusID":"6","companyTruncated":"Amolyt Pharma \/ PeptiDream"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":1.05,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":1.05,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Eneboparatide","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Amolyt Pharma","amount2":1.05,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Amolyt Pharma \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Amolyt Pharma \/ AstraZeneca"}]

    Find Clinical Drug Pipeline Developments & Deals by Amolyt Pharma

    Menu

    Amolyt Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II/ Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $1,050.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AstraZeneca Closes Acquisition of Amolyt Pharma

                            Details : Through the acquisition, AstraZeneca leverages the AZP-3601 (neboparatide), peptide agonist of the PTH1 receptor. Currently, being evaluated for the treatment of Chronic Hypoparathyroidism.

                            Brand Name : AZP-3601

                            Molecule Type : Peptide

                            Upfront Cash : $800.0 million

                            July 15, 2024

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $1,050.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amolyt Pharma Granted FDA Fast Track for Eneboparatide in Hypoparathyroidism

                            Details : AZP-3601 (neboparatide) is a peptide agonist of the PTH1 receptor. Currently, being evaluated in the Phase III for Chronic Hypoparathyroidism, Endocrine System Diseases, and Parathyroid Diseases.

                            Brand Name : AZP-3601

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 02, 2024

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $1,050.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

                            Details : AstraZeneca leverages AZP-3601 (neboparatide), a peptide agonist of the PTH1 receptor, currently in Phase III for treating chronic hypoparathyroidism and related endocrine diseases.

                            Brand Name : AZP-3601

                            Molecule Type : Peptide

                            Upfront Cash : $800.0 million

                            March 14, 2024

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $1,050.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZP-3813

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : PeptiDream

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GH...

                            Details : AZP-3813, a peptide GHR antagonist, is being developed as a potential treatment for acromegaly to be used in combination with somatostatin analogues (SSAs) for patients who do not adequately respond to SSAs alone.

                            Brand Name : AZP-3813

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 05, 2023

                            Lead Product(s) : AZP-3813

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : PeptiDream

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amolyt Pharma Announces Phase 3 Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism Follow...

                            Details : AZP-3601 (eneboparatide) targets PTH receptor to safely produce sustained blood levels of calcium and thereby manage the symptoms of hypoparathyroidism, and to limit urine calcium excretion by restoring calcium reabsorption by the kidney, preventing chro...

                            Brand Name : AZP-3601

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 02, 2023

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZP-40XX

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Recipient : XOMA

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

                            Details : Amolyt will advance pre-clinical development of AZP-40XX, an anti-PTHR1 monoclonal antibody, as potential treatments of primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM).

                            Brand Name : AZP-40XX

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : AZP-40XX

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : XOMA

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Sofinnova Partners

                            Deal Size : $138.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate C...

                            Details : Amolyt plans to use the proceeds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly.

                            Brand Name : AZP-3601

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 06, 2023

                            Lead Product(s) : Eneboparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Sofinnova Partners

                            Deal Size : $138.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZP-3601

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amolyt Pharma to Present Full Phase 2a Data on AZP-3601 at Upcoming Conferences

                            Details : AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyro...

                            Brand Name : AZP-3601

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 12, 2022

                            Lead Product(s) : AZP-3601

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZP-3601

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amolyt Pharma Announces Positive Safety and Efficacy Results from Second Patient Cohort in its Phase 2a Trial ...

                            Details : AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyro...

                            Brand Name : AZP-3601

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 12, 2022

                            Lead Product(s) : AZP-3601

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Amolyt Pharma

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZP-3601

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study of AZP-3601 in P...

                            Details : AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyro...

                            Brand Name : AZP-3601

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 12, 2022

                            Lead Product(s) : AZP-3601

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth